RecruitingNot ApplicableNCT04837339

Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation

Sponsor

Hopital Foch

Enrollment

900 participants

Start Date

Mar 17, 2022

Study Type

INTERVENTIONAL

Conditions

Lung Transplant; Complications Lung Transplant Rejection Lung Transplant Failure Lung Transplant Failure and Rejection

Summary

Transplant results vary considerably from one organ to another. Lung transplantation has poorer long-term outcomes than other solid organ transplants, with a current median post-transplant survival of 6.0 years. Allograft rejection remains the leading cause of morbidity and mortality in all organ groups and is the leading cause of death, accounting for more than 40% of deaths beyond the first year after lung transplantation. Each dysfunctions impacts the fate of the graft and therefore the survival of the recipient. Their early and precise diagnosis is therefore a major issue. The identification of the pathophysiological mechanisms underlying these different subtypes of dysfunction (transcriptomics, polymorphism of target genes of the immune system or tissue repair, cell phenotyping) is an essential step. It can only be done on the basis of a collection of samples linked to a clinical database allowing to contextualize each sample.

Eligibility

Min Age: 15 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting biological samples and clinical data from patients who have had, or are waiting for, a lung transplant to identify biomarkers that can predict transplant dysfunction. Lung transplant recipients face a significant risk of chronic lung allograft dysfunction (CLAD) — a condition where the transplanted lungs gradually lose function — and early identification could allow for earlier intervention. Researchers will analyze blood samples and other biological materials over time to find molecular signals that predict which patients will develop complications and which will maintain healthy transplant function. This kind of research could eventually lead to personalized monitoring and treatment strategies. You may be eligible if: - You are over 15 years old - You are scheduled for a lung transplant at Foch Hospital or are already being followed there after a lung transplant - You have signed the informed consent (and if aged 15–18, your parent/guardian has also signed) - You are affiliated with a health insurance plan You may NOT be eligible if: - You are pregnant, recently gave birth, or are breastfeeding - Your hemoglobin level is 8 g/dL or below (severe anemia) - You are unable to consent independently (under legal protection) without a guardian present Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.